Contemporary OB/GYN Staff

Articles by Contemporary OB/GYN Staff

About 1 in every 5 women (18%) who receives breast-conserving surgery for breast cancer receives a second operation within 3 months. And reoperation is almost twice as likely (29%) in those with carcinoma in situ (CIS). Furthermore, 1 in 7 women who choose breast-conserving surgery as their reoperation require additional surgery.

Not exactly, says Courtney Denning-Johnson Lynch, PhD, MPH, lead author of a new prospective cohort study published in Fertility and Sterility. The latest results seem to show that stress, anxiety, and depression self-reported by women via questionnaires do no correlate with fecundity, but she says the lack of an association really lies with the inadequacy of questionnaires.

Drinking more than 4 alcoholic beverages per week reduces risk of rheumatoid arthritis (RA) in women by about 37% compared with women who drink less than 1 alcohol-containing beverage weekly or who never drink, according to the findings of a recent study published in the British Medical Journal.

Cranberry-containing products may be more than just a folk remedy for urinary tract infections (UTIs). A systematic review and meta-analysis published in the Archives of Internal Medicine concludes that cranberry-containing products offer women protection against UTIs, particularly those prone to recurrent infections.

The etonogestrel subdermal contraceptive implant is just as effective in overweight and obese women as it is in women of normal weight and is as effective as an intrauterine device (IUD) (either the levonorgestrel intrauterine system or copper T380A), according to a recent study in Obstetrics and Gynecology.

The United States Food and Drug Administration (FDA), under its priority review program, recently approved PerjetaTM (pertuzumab), a HER2/neu receptor antagonist indicated in combination with HerceptinR (trastuzumab), another HER2 therapy, and docetaxel for treatment of HER2-positive metastatic breast cancer (BCa) in women who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Analysis by the United States Food and Drug Administration (FDA) of compounded 17α-hydroxyprogesterone caproate (17P) shows the samples meet the potency and total purity standards for Makena, the branded version of the drug. Testing was done on 16 samples of bulk 17P active pharmaceutical ingredients (API) in response to questions from K-V Pharmaceuticals, Makena’s sponsor, about potency and purity of the compounded product.